Synergy Pharmaceuticals to Present at AACR
Synergy's second GC-C agonist SP-333 is at present in pre-clinical development to treat inflammatory bowel diseases. Much more details is accessible at https://www.synergypharma.com . Fox Chase Cancer Center is 1 of the top cancer study and …
Read far more on MarketWatch (press release)
Canadian College of Naturopathic Medicine Opens 1st Integrative Cancer …
The OICC is each a therapy clinic and an integrative oncology analysis centre, which exists to assess and decrease attainable causes of cancer even though exploring innovative integrative strategies to treat the illness. The Centre's clinical practice and …
Read more on Canada NewsWire (press release)
Leave a Reply
You must be logged in to post a comment.